Hypereosinophilia and acute lymphocytic leukemia [PDF]
, 1991 Eduardo Ríos +3 more
openalex +1 more source
Engineering Immune Cell to Counteract Aging and Aging‐Associated Diseases
Advanced Science, EarlyView.This review highlights a paradigm shift in which advanced immune cell therapies, initially developed for cancer, are now being harnessed to combat aging. By engineering immune cells to selectively clear senescent cells and remodel pro‐inflammatory tissue microenvironments, these strategies offer a novel and powerful approach to delay age‐related ...
Jianhua Guo +5 more
wiley +1 more source
INITIAL GENETIC DIAGNOSIS IN ACUTE LYMPHOCYTIC LEUKEMIA (ALL). 947 [PDF]
, 1996 Éva Oláh +3 more
openalex +1 more source
Advanced Science, EarlyView.We analyzed long‐read genomic sequencing data obtained from 40 inbred mouse strains to produce a large database of structural variants. This dataset captures the major types of structural variants, which includes deletions, insertions, duplications, and inversions.
Wenlong Ren +6 more
wiley +1 more source
Survival Rate of Patients with Acute Leukemia: A Case Study in Iran
Journal of Evidence Based Health Policy, Management & Economics, 2020 Background: Acute leukemia is a kind of aggressive disease that includes high rates of fatalities in the world, in particular in Iran. This research was done to determine the survival rate of patients with acute leukemia in Iran.
Mohammad Ranjbar +4 more
doaj
Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia [PDF]
, 1988 HM Kantarjian +6 more
openalex +1 more source
ALLNet: A Hybrid Convolutional Neural Network to Improve Diagnosis of Acute Lymphocytic Leukemia (ALL) in White Blood Cells [PDF]
, 2021 Sai Mattapalli, Rishi Athavale
openalex +1 more source
Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia [see comments] [PDF]
, 1990 TC Meeker +4 more
openalex +1 more source
A Murine Bispecific Antibody Efficiently Redirects T Cells Against Calr Mutated Stem Cells In Vivo
American Journal of Hematology, EarlyView.ABSTRACT Calreticulin (CALR) mutations are prevalent in 20%–30% of patients with BCR::ABL1‐negative myeloproliferative neoplasms (MPN). Mutant calreticulin (mutCALR), presented by the thrombopoietin receptor (MPL, also known as TPOR or CD110) on the surface of the disease‐initiating MPN progenitors, represents an ideal target for curative ...
Shengen Xiong +5 more
wiley +1 more source